What does Connecticut HB 5127 do?

CT HB 5127 — An Act Concerning Credit Cards and Health and Veterinary Care Services, signed May 7, 2026 and effective January 1, 2027 — prohibits Connecticut health and veterinary care providers from advertising, marketing, soliciting, promoting, or offering medical credit cards to consumers; receiving any compensation from financing companies for promoting their products; assisting a patient in acquiring a medical credit card; and charging a financing account for services before they are rendered. It also requires specific written disclosures if a patient independently asks about financing — including that the product is a third-party loan, not a payment plan with the practice, and that deferred-interest products can trigger retroactive interest on the full original balance.

Does CT HB 5127 apply to dental practices?

Yes — squarely. The law covers all health care providers, and veterinary providers as well; dental practices are not singled out, but no field leans on the targeted products harder. Third-party medical credit cards are the dominant mechanism dental practices use to bridge the gap between insurance maximums (commonly still around $1,500) and comprehensive treatment costs — which makes dentistry the specialty where the marketing and facilitation ban bites deepest.

Can dental practices still accept CareCredit in Connecticut after the law takes effect?

Accepting is not the issue — promoting is. From January 1, 2027, a Connecticut practice cannot advertise or offer the card, cannot help a patient apply, cannot be compensated for promotion, and cannot charge the account before services are rendered. A patient who independently obtains a medical credit card can still use it, and if a patient asks about financing, the provider may respond — but must deliver the required written disclosures. The operational consequence: the proactive in-office financing conversation that treatment coordinators use to close high-value cases is what the law removes.

Why does a medical credit card law affect dental practice valuations?

Because buyers price predictability, and a legislated revenue mechanism is no longer predictable. When a Quality of Earnings team underwrites a practice in a state with HB 5127-style law — passed or advancing — it will quantify what percentage of high-value case acceptance depends on in-office financing facilitation, and discount projected earnings accordingly. The buyer is not purchasing your historical case acceptance rate; they are purchasing your projected rate in the post-legislation operating environment. A broker cannot argue with a signed law, and a CPA cannot add back a legislative risk discount.

Will other states pass laws like CT HB 5127?

The conditions for it are in place. The Consumer Financial Protection Bureau flagged medical credit card practices in a 2023 report, Connecticut's Attorney General pushed for protections beyond the final bill, and the legislative template is now written, tested, and signed. Growth in the underlying product is documented — one issuer reported its active Connecticut accounts rising from 65,000 to over 100,000 by February 2026. None of this guarantees any particular state acts, but sellers planning a 3-5 year exit should treat copycat legislation as a scenario buyers will model — because buyers already do.

How do I protect my practice's value from legislative risk?

You cannot lobby your way out of a QoE audit — you can only reduce the dependency being priced. Start by measuring it: what percentage of accepted high-value treatment involves third-party financing facilitation (a number most practices have never pulled, and buyers will). Then build case acceptance that survives without the crutch: documented, SOP-driven treatment presentation, trained financial conversations within the law's disclosure framework, and diversified payment pathways. That work belongs in the 3-5 year pre-exit window — a practice whose acceptance rate is demonstrably independent of any single financing rail has nothing for the legislative discount to attach to.

Industry Insights

The Legislative Squeeze and the Pricing of Risk: Why CT HB 5127 Matters to Your M&A Exit

Joe DeLuca August 7, 2026 8 min read

For the last decade, the dental M&A environment has operated like the Wild West. Institutional money flooded the zone, Private Equity roll-ups aggressively consolidated the market, and third-party financing companies built a lucrative business model off the gap between what insurance covers and what comprehensive dentistry actually costs.

But the era of flying under the radar is officially over. State legislatures are waking up, and Connecticut House Bill 5127 — signed into law on May 7, 2026 — is the clearest warning shot yet.

Whether you practice in Connecticut, California, or Texas, you need to understand what this legislation actually targets: the third-party patient financing model that dental practices depend on to close high-value treatment plans. And in the world of M&A, when a core revenue mechanism gets legislated, buyers do not absorb that risk. They price it into your valuation.

What CT HB 5127 actually does

CT HB 5127 is not a dental loss ratio bill. It is not a network leasing reform. It is a direct strike at the relationship between healthcare providers and third-party medical credit card companies — specifically products like CareCredit, the Synchrony Bank product that is the dominant financing vehicle in the dental industry. The law’s scope is broad — it covers every health care provider in the state, and veterinary practices too — but no field leans on these products harder than dentistry, which puts dental practices at the center of the blast radius.

Effective January 1, 2027, the law prohibits Connecticut providers from:

Provision	What it means in the operatory
No advertising, marketing, soliciting, promoting, or offering a medical credit card	The brochure in the consult room, the logo on the website, the treatment coordinator’s pitch — all gone
No financial incentives or compensation from financing companies	Promotion economics between lender and practice are severed
No assisting a patient in acquiring a medical credit card	Staff cannot walk a patient through the application
No charging a financing account before services are rendered	Pre-charging for treatment plans ends
Required written disclosures if a patient independently asks	Must state it is a third-party loan, not a practice payment plan, and explain deferred-interest risk

Source: CT HB 5127, “An Act Concerning Credit Cards and Health and Veterinary Care Services” (2026); official bill analysis, Connecticut General Assembly.

The legislative motivation is straightforward, and parts of it are genuinely defensible. CareCredit’s standard APR is 32.99% once a deferred-interest promotional period expires — and if a patient hasn’t paid the full balance by the end of the term, they owe interest on the original loan amount, not just the remaining balance. Consumer advocates have compared deferred-interest products to legalized loan-sharking. The Connecticut Attorney General’s office pushed for protections that went even further than the final bill. It passed with broad sponsorship and was signed by the governor.

Here is the honest truth: the transparency provisions in this bill are not the enemy. A well-run practice should already be coaching its team to this language. Calling CareCredit “zero interest” is misleading and creates patient resentment when the 32.99% hits at month 13. The right conversation with a patient is: “This is a medical credit card — it’s usable at thousands of healthcare providers, not just here. It carries deferred interest, not zero interest. If you pay it off within your promotional term, you pay nothing extra. If you don’t, the full interest rate applies retroactively to the original balance.” That is a more honest conversation, and it produces a better patient relationship.

The transparency requirements are not what should concern you. The marketing and facilitation ban is.

Why this matters far beyond Connecticut

Connecticut is not an outlier. It is the canary.

The Consumer Financial Protection Bureau flagged predatory medical credit card practices in a 2023 report. The product’s growth is documented in Connecticut’s own legislative record: one issuer reported its active accounts in the state climbing from 65,000 to more than 100,000 by February 2026 — roughly 50% growth in under four years. Multiple states are watching Connecticut’s implementation. The legislative template has been written, tested, and signed. Copycat bills should be treated as a planning scenario, because buyers already treat them as one.

For dental practices, the implications are direct. Third-party financing is the bridge that makes high-value, comprehensive dentistry accessible to patients whose insurance maximum is still anchored to 1973. It is the mechanism that allows a treatment coordinator to close a $4,500 case when the patient’s insurance maximum is $1,500.

When that bridge gets legislated out of the provider’s hands — when the treatment coordinator can no longer proactively introduce the financing option during the case presentation — the patient has to seek it out independently. And the data on patient behavior is unambiguous: friction kills case acceptance. The moment you remove the in-office financing conversation from the treatment presentation, a meaningful percentage of comprehensive cases simply do not close. The patient leaves to “think about it” and never comes back. In one PDA forensic case, third-party financing utilization was running at 0.4% — and diagnosed-but-unscheduled treatment was measured in the millions. That is what the affordability gap does with the financing rail available. Now remove the rail.

The M&A valuation consequence

When a Private Equity firm or institutional buyer underwrites your practice, they are projecting your cash flow five years into the future. Their entire valuation model depends on predictability.

If your practice is in a state that has passed CT HB 5127-style legislation — or where similar bills are advancing — the buyer’s Quality of Earnings team will immediately ask one question: What percentage of your high-value case acceptance is dependent on in-office third-party financing facilitation?

If the answer is significant, the buyer now has a documented, legislatively-grounded argument to compress your valuation. They are not buying your historical case acceptance rate. They are buying your projected case acceptance rate in a post-HB-5127 operating environment. And those are two very different numbers.

Your broker cannot argue with a signed law. Your CPA cannot add back a legislative risk discount. The only thing that protects your valuation in this environment is a clinical baseline that demonstrates your team can close comprehensive cases through documented, SOP-driven treatment presentation — independent of the financing crutch.

Controlling the ledger

You cannot control what happens in Hartford, Sacramento, or Austin. You cannot lobby your way out of an institutional QoE audit.

The only way to bulletproof your valuation against macro-level legislative risk is to build a micro-level fortress. You have to forensically harden your clinical baseline.

Practices that command premium multiples in a heavily regulated environment are the ones that have eliminated their dependency on volatile systems. They have eradicated Habit Debt. They have broken free from the 1973 Anchor of heavily discounted PPOs. They possess hardened, repeatable Standard Operating Procedures that generate revenue regardless of what a state legislature does next quarter.

The practices that will be penalized the hardest are the ones that waited. The ones that went to market with a case acceptance model built entirely on the assumption that the in-office financing conversation would always be available — and never built the clinical infrastructure to close cases without it.

Legislators are going to keep drafting bills. Buyers are going to keep using those bills to compress valuations.

Your only defense is your data. And the time to build that defense is not 30 days before your LOI — it is 3 to 5 years before you ever call a broker.

Educational, not legal advice — the law’s requirements and effective dates are as enacted at publication; compliance specifics for your practice belong with your healthcare attorney. To measure the dependency a buyer will price — including your financing-linked case acceptance — start with the EBITDA Leakage Diagnostic.

Sources: CT HB 5127 (2026), Connecticut General Assembly bill records and official bill analysis; Governor’s Bill Notification 2026-5 (signed May 7, 2026); CareCredit published account terms (32.99% standard APR); Consumer Financial Protection Bureau, medical credit card report (2023); Connecticut legislative testimony record (issuer account growth, February 2026).

About the author — Joe DeLuca is Chief Analytics Officer & Co-Principal of Precision Dental Analytics, a metrics-based practice architect with DSO turnaround experience across 100+ locations at Aspen Dental and NADG. He builds the benchmarking architecture behind PDA’s M&A defense and growth engagements, and is the author of The Root of Leadership. Meet the team →

Frequently Asked

Questions

What does Connecticut HB 5127 do?: CT HB 5127 — An Act Concerning Credit Cards and Health and Veterinary Care Services, signed May 7, 2026 and effective January 1, 2027 — prohibits Connecticut health and veterinary care providers from advertising, marketing, soliciting, promoting, or offering medical credit cards to consumers; receiving any compensation from financing companies for promoting their products; assisting a patient in acquiring a medical credit card; and charging a financing account for services before they are rendered. It also requires specific written disclosures if a patient independently asks about financing — including that the product is a third-party loan, not a payment plan with the practice, and that deferred-interest products can trigger retroactive interest on the full original balance.
Does CT HB 5127 apply to dental practices?: Yes — squarely. The law covers all health care providers, and veterinary providers as well; dental practices are not singled out, but no field leans on the targeted products harder. Third-party medical credit cards are the dominant mechanism dental practices use to bridge the gap between insurance maximums (commonly still around $1,500) and comprehensive treatment costs — which makes dentistry the specialty where the marketing and facilitation ban bites deepest.
Can dental practices still accept CareCredit in Connecticut after the law takes effect?: Accepting is not the issue — promoting is. From January 1, 2027, a Connecticut practice cannot advertise or offer the card, cannot help a patient apply, cannot be compensated for promotion, and cannot charge the account before services are rendered. A patient who independently obtains a medical credit card can still use it, and if a patient asks about financing, the provider may respond — but must deliver the required written disclosures. The operational consequence: the proactive in-office financing conversation that treatment coordinators use to close high-value cases is what the law removes.
Why does a medical credit card law affect dental practice valuations?: Because buyers price predictability, and a legislated revenue mechanism is no longer predictable. When a Quality of Earnings team underwrites a practice in a state with HB 5127-style law — passed or advancing — it will quantify what percentage of high-value case acceptance depends on in-office financing facilitation, and discount projected earnings accordingly. The buyer is not purchasing your historical case acceptance rate; they are purchasing your projected rate in the post-legislation operating environment. A broker cannot argue with a signed law, and a CPA cannot add back a legislative risk discount.
Will other states pass laws like CT HB 5127?: The conditions for it are in place. The Consumer Financial Protection Bureau flagged medical credit card practices in a 2023 report, Connecticut's Attorney General pushed for protections beyond the final bill, and the legislative template is now written, tested, and signed. Growth in the underlying product is documented — one issuer reported its active Connecticut accounts rising from 65,000 to over 100,000 by February 2026. None of this guarantees any particular state acts, but sellers planning a 3-5 year exit should treat copycat legislation as a scenario buyers will model — because buyers already do.
How do I protect my practice's value from legislative risk?: You cannot lobby your way out of a QoE audit — you can only reduce the dependency being priced. Start by measuring it: what percentage of accepted high-value treatment involves third-party financing facilitation (a number most practices have never pulled, and buyers will). Then build case acceptance that survives without the crutch: documented, SOP-driven treatment presentation, trained financial conversations within the law's disclosure framework, and diversified payment pathways. That work belongs in the 3-5 year pre-exit window — a practice whose acceptance rate is demonstrably independent of any single financing rail has nothing for the legislative discount to attach to.